EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: a randomized, double-blind, placebo-controlled trial

Ahmad Shamabadi, Elham-Sadat Rafiei-Tabatabaei, Kimia Kazemzadeh, Kimia Farahmand, Bita Fallahpour, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzadeh

International Journal of Neuropsychopharmacology · 2024

DOI: 10.1093/ijnp/pyae051 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Neuropsychopharmacology, 2024. Verfasst von Ahmad Shamabadi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Schizophrenia, Pentoxifylline, Risperidone, Antipsychotic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tehran University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Negative symptoms of schizophrenia represent an unmet therapeutic need for many patients in whom pentoxifylline may be effective in terms of its dopaminergic, anti-inflammatory, and cerebral blood flow–increasing properties. This study aimed to evaluate pentoxifylline as a therapeutic agent for improving negative symptoms of schizophrenia.

Methods

Chronic schizophrenia outpatients experiencing significant negative symptoms were randomly allocated to receive pentoxifylline 400 mg or matched placebo every 12 hours for 8 weeks. All patients were clinically stable as they had received risperidone for at least 2 months, which was continued. The participants were assessed using the Positive and Negative Syndrome Scale (PANSS), Hamilton Depression Rating Scale, Extrapyramidal Symptom Rating Scale, and side effect checklist.

Results

The patients’ baseline characteristics were comparable between the groups. There was a significant time–treatment interaction effect on PANSS negative subscale scores (ηP2=0.075), with the pentoxifylline group showing significantly greater reductions until weeks 4 (Cohen d = 0.512) and 8 (Cohen d = 0.622). Also, this group showed a significantly better response by week 8. Other PANSS scores, Hamilton Depression Rating Scale scores, Extrapyramidal Symptom Rating Scale scores, and side effect frequencies were comparable between the groups. Pentoxifylline showed a nonsignificant higher remission of 37.1% compared with 14.7% in the placebo group.

Conclusions

Pentoxifylline was safely and tolerably beneficial for the primary negative symptoms of chronic schizophrenia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaPentoxifyllineRisperidoneAntipsychotic AgentsOutcome Assessment, Health CareHumansMaleFemaleDouble-Blind MethodAdultMiddle AgedDrug Therapy, CombinationPsychiatric Status Rating ScalesYoung AdultTreatment Outcome

Stichwörter der Autor:innen

combination drug therapyneuroimmunomodulationpsychosispsychotic disorderrandomized controlled trial

Substanzen

PentoxifyllineRisperidoneAntipsychotic Agents

Autor:innen und Institutionen

  • Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Psychiatry, Razi Hospital, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Förderung

  • Tehran University of Medical Sciences

Zitieren

APA

Shamabadi, A., Rafiei-Tabatabaei, E. S., Kazemzadeh, K., Farahmand, K., Fallahpour, B., Khodaei Ardakani, M. R., & Akhondzadeh, S. (2024). Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyae051

Vancouver

Shamabadi A, Rafiei-Tabatabaei ES, Kazemzadeh K, Farahmand K, Fallahpour B, Khodaei Ardakani MR, et al. Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacology. 2024. doi:10.1093/ijnp/pyae051

BibTeX
@article{Shamabadi2024,
  author = {Shamabadi, Ahmad and Rafiei-Tabatabaei, Elham-Sadat and Kazemzadeh, Kimia and Farahmand, Kimia and Fallahpour, Bita and Khodaei Ardakani, Mohammad-Reza and Akhondzadeh, Shahin},
  title = {Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: a randomized, double-blind, placebo-controlled trial},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2024},
  doi = {10.1093/ijnp/pyae051}
}
Kostenlos starten →